Jiangxi Rimag Group Co., Ltd.

SEHK:2522 Stock Report

Market Cap: HK$22.7b

Jiangxi Rimag Group Valuation

Is 2522 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2522 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2522 (HK$63.7) is trading above our estimate of fair value (HK$47.44)

Significantly Below Fair Value: 2522 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2522?

Key metric: As 2522 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2522. This is calculated by dividing 2522's market cap by their current revenue.
What is 2522's PS Ratio?
PS Ratio26.2x
SalesCN¥812.85m
Market CapCN¥21.33b

Price to Sales Ratio vs Peers

How does 2522's PS Ratio compare to its peers?

The above table shows the PS ratio for 2522 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
1951 Jinxin Fertility Group
2.5x11.7%HK$7.8b
2273 Gushengtang Holdings
2.7x24.7%HK$7.8b
6606 New Horizon Health
4.3x20.5%HK$6.3b
9860 Adicon Holdings
1.4x9.0%HK$4.7b
2522 Jiangxi Rimag Group
26.2x30.0%HK$22.7b

Price-To-Sales vs Peers: 2522 is expensive based on its Price-To-Sales Ratio (26.2x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does 2522's PS Ratio compare vs other companies in the HK Healthcare Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
1099 Sinopharm Group
0.1x5.5%US$8.82b
9955 ClouDr Group
0.2x23.5%US$89.94m
6833 Sinco Pharmaceuticals Holdings
0.1xn/aUS$48.68m
2211 Universal Health International Group Holding
0.1xn/aUS$17.74m
2522 26.2xIndustry Avg. 0.9xNo. of Companies9PS00.81.62.43.24+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2522 is expensive based on its Price-To-Sales Ratio (26.2x) compared to the Hong Kong Healthcare industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is 2522's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2522 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26.2x
Fair PS Ratio3.6x

Price-To-Sales vs Fair Ratio: 2522 is expensive based on its Price-To-Sales Ratio (26.2x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:09
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangxi Rimag Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yu WuCMB International Securities Limited